These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29444901)

  • 1. Intensive Hemodialysis Fails to Reduce Plasma Levels of Uremic Solutes.
    Sirich TL; Meyer TW
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):361-362. PubMed ID: 29444901
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
    Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
    PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uremic Solutes Produced by Colon Microbes.
    Tanaka H; Sirich TL; Meyer TW
    Blood Purif; 2015; 40(4):306-11. PubMed ID: 26656941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Enlarged Profile of Uremic Solutes.
    Tanaka H; Sirich TL; Plummer NS; Weaver DS; Meyer TW
    PLoS One; 2015; 10(8):e0135657. PubMed ID: 26317986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic analysis of uremic pruritus in patients on hemodialysis.
    Bolanos CG; Pham NM; Mair RD; Meyer TW; Sirich TL
    PLoS One; 2021; 16(2):e0246765. PubMed ID: 33577623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CE-MS-Based Identification of Uremic Solutes Specific to Hemodialysis Patients.
    Akiyama Y; Kikuchi K; Toyohara T; Mishima E; Suzuki C; Suzuki T; Nakayama M; Tomioka Y; Soga T; Abe T
    Toxins (Basel); 2021 Apr; 13(5):. PubMed ID: 33946481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal disease.
    Jhawar S; Singh P; Torres D; Ramirez-Valle F; Kassem H; Banerjee T; Dolgalev I; Heguy A; Zavadil J; Lowenstein J
    PLoS One; 2015; 10(3):e0118703. PubMed ID: 25811877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.
    Zhang ZH; Mao JR; Chen H; Su W; Zhang Y; Zhang L; Chen DQ; Zhao YY; Vaziri ND
    Clin Biochem; 2017 Dec; 50(18):1078-1086. PubMed ID: 28928007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clearance of unidentified uremic solutes (with molecular weight under 5 kDa) plays an important role in hemodialyzer selection.
    Chen TS; Liou SY; Chang YL
    Int Urol Nephrol; 2010 Jun; 42(2):465-70. PubMed ID: 19590973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial.
    Sirich TL; Fong K; Larive B; Beck GJ; Chertow GM; Levin NW; Kliger AS; Plummer NS; Meyer TW;
    Kidney Int; 2017 May; 91(5):1186-1192. PubMed ID: 28089366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.
    Miyata T; Ueda Y; Yamada Y; Izuhara Y; Wada T; Jadoul M; Saito A; Kurokawa K; van Ypersele de Strihou C
    J Am Soc Nephrol; 1998 Dec; 9(12):2349-56. PubMed ID: 9848790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonic contribution to uremic solutes.
    Aronov PA; Luo FJ; Plummer NS; Quan Z; Holmes S; Hostetter TH; Meyer TW
    J Am Soc Nephrol; 2011 Sep; 22(9):1769-76. PubMed ID: 21784895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma metabolomics profiling of maintenance hemodialysis based on capillary electrophoresis - time of flight mass spectrometry.
    Liu S; Wang L; Hu C; Huang X; Liu H; Xuan Q; Lin X; Peng X; Lu X; Chang M; Xu G
    Sci Rep; 2017 Aug; 7(1):8150. PubMed ID: 28811533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip.
    Klin M; Waluga M; Rudka R; Madej A; Janiszewska M; Grzebieniak E; Wesolowky A
    Boll Chim Farm; 1998 Sep; 137(8):306-13. PubMed ID: 9835145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.
    Mutsaers HA; Engelke UF; Wilmer MJ; Wetzels JF; Wevers RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
    PLoS One; 2013; 8(8):e71199. PubMed ID: 23936492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obstacles to reducing plasma levels of uremic solutes by hemodialysis.
    Sirich TL
    Semin Dial; 2017 Sep; 30(5):403-408. PubMed ID: 28558415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid metabolism in uremia: effect of regular hemofiltration and hemodialysis treatment.
    Henning HV; Balusek E
    J Dial; 1977; 1(6):595-605. PubMed ID: 608870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of uremia and hemodialysis on the plasma protein binding of tolmetin.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Pharmacology; 1984; 29(6):312-9. PubMed ID: 6505005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor.
    Chitalia VC; Shivanna S; Martorell J; Balcells M; Bosch I; Kolandaivelu K; Edelman ER
    Circulation; 2013 Jan; 127(3):365-76. PubMed ID: 23269489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.